<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911271</url>
  </required_header>
  <id_info>
    <org_study_id>Line Kessel, RH-Glostrup</org_study_id>
    <nct_id>NCT03911271</nct_id>
  </id_info>
  <brief_title>Low-dose Atropine for the Prevention of Myopia Progression in Danish Children</brief_title>
  <acronym>APP</acronym>
  <official_title>Low-dose Atropine for the Prevention of Myopia Progression in Danish Children - a Randomized, Double-masked, Multicenter, 36-month Prospective 1:1:1 Study of Safety and Efficacy of 0.1% Atropine Loading Dose to Single 0.01% Atropine and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Line Kessel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myopia (nearsightedness) is increasing in prevalence throughout the world. It is associated&#xD;
      with a risk of potentially blinding complications such as retinal detachment and myopic&#xD;
      maculopathy. There is a direct association between the degree of myopia and the risk of&#xD;
      complications. Myopia develops in childhood and during adolescence. To prevent higher degrees&#xD;
      of myopia, we need to halt disease progression in children and teenagers. Low-dose atropine&#xD;
      eye drops have been shown to reduce myopia progression by 50% in Asian populations but its&#xD;
      effect in non-Asian populations is unknown. The aim of this study is to investigate if&#xD;
      low-dose atropine can reduce myopia progression in Danish children and teenagers. The study&#xD;
      is an investigator initiated randomized clinical trial conducted as a collaboration between&#xD;
      three Danish Eye Departments covering all of Denmark.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main hypotheses tested in this study are:&#xD;
&#xD;
        -  0.01% atropine one drop nightly reduces the progression of childhood myopia in Danish&#xD;
           children.&#xD;
&#xD;
        -  0.01% atropine one drop nightly is safe and with no significant side effects.&#xD;
&#xD;
        -  A 6-month loading dose of 0.1% atropine followed by a 0.01% atropine maintenance dose is&#xD;
           superior to single 0.01% atropine.&#xD;
&#xD;
        -  0.1% atropine one drop nightly is safe and has tolerable side effects.&#xD;
&#xD;
        -  The rebound effect after stopping both atropine regimens is limited.&#xD;
&#xD;
        -  Choroidal thickness is a predictor for the progression of childhood myopia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in axial length</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment group comparison of change in axial length elongation from baseline to 36 months, as measured using IOLMaster 700</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in spherical equivalent</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment group comparison of change in spherical equivalent from baseline to 36 months, as measured using cycloplegic autorefraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects and reactions</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment group comparison of adverse effects and reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in choroidal thickness</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment group comparison of change in choroidal thickness from baseline to 36 months, as measured using optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ocular biometry</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment group comparison of change in ocular biometry (i.e. keratometry, anterior chamber depth, lens thickness, vitreous axial distance) from baseline to 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in higher-order aberrations</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment group comparison of change in higher-order aberrations from baseline to 36 months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Loading dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In phase 1 (treatment phase), the participants (n=50) will receive 0.1% atropine loading dose for 6 months followed by 0.01 % atropine for 18 months. The eye drops are administered as one eye drop daily in each eye at bedtime.&#xD;
In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In phase 1 (treatment phase), the participants (n=50) will receive 0.01 % atropine for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.&#xD;
In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In phase 1 (treatment phase), the participants (n=50) will receive placebo eye drops for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.&#xD;
In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% atropine and 0.01% atropine</intervention_name>
    <description>0.1% atropine loading dose for 6 months followed by 0.01% atropine for 18 months</description>
    <arm_group_label>Loading dose</arm_group_label>
    <other_name>Loading dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.01% atropine</intervention_name>
    <description>0.01% atropine for 24 months</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Low-dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Sodium-chloride</intervention_name>
    <description>Placebo for 24 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children aged ≥6-&lt;9 years: myopia ≤-1 (spherical power) in at least one eye&#xD;
&#xD;
          -  Children aged ≥9-≤12 years: myopia ≤-2 (spherical power) in at least one eye&#xD;
&#xD;
          -  Cylinder less than 1.5 diopters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myopia related to retinal dystrophies&#xD;
&#xD;
          -  Collagen syndroms (Ehlers-Danlos syndrome, Marfan syndrome and Stickler syndrome)&#xD;
&#xD;
          -  Other ocular pathology (e.g., amblyopia, strabismus)&#xD;
&#xD;
          -  Previous eye surgery&#xD;
&#xD;
          -  Previous use of agents thought to affect myopia progression, e.g. atropine,&#xD;
             pirenzepine or 7-methylxanthine (metabolite of caffeine and theobromine) and&#xD;
             orthokeratology contact lenses&#xD;
&#xD;
          -  Known allergy to atropine or any of the contents of the trial medication (active and&#xD;
             in-active ingredients) used in the study&#xD;
&#xD;
          -  Non-compliance to eye examinations&#xD;
&#xD;
          -  Serious systemic health troubles (e.g., cardiac or respiratory illness) and&#xD;
             developmental disorders and delays&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Ophthalmology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, Rigshospitalet-Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Line Kessel</investigator_full_name>
    <investigator_title>Consultant ophthalmologist, Associate Professor, MD, Ph.D., FEBO</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

